



FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG

January 26, 2015

CARDIOCOMM SOLUTIONS CONFIRMS AUSTRALIAN REGULATORY CLEARANCE FOR OVER THE COUNTER (OTC) SALES OF THE HEARTCHECK™ ECG PEN

Cardiac Innovations Australia will promote sales of HeartCheck™ devices to medical and retail markets

TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”), a global medical provider of electrocardiogram (“ECG”) acquisition and management software solutions, today announced that it has received clearance from the Australian Department of Health, Therapeutics Goods Administration (“TGA”) for the sale and marketing of their hand-held ECG monitoring devices known as the HeartCheck™ ECG PEN, the HeartCheck™ ECG Monitor and GEMS™ Home in Australia.

CardioComm Solutions previously announced that the Australian TGA granted a certificate for the sale of the Company’s GEMS™ WIN medical software technologies and that the Company had signed Cardiac Innovations Australia Pty. Ltd. (“Cardiac Innovations”) to be the Company’s representative and distributor of its products in Australia. The recent TGA clearance for CardioComm Solutions now provides an expanded sales opportunity for the HeartCheck™ ECG devices and associated SMART Monitoring ECG service solution into the Australian medical, allied health, and consumer markets.

The handheld HeartCheck™ ECG devices can be connected to a Windows based computer to upload recorded ECGs to CardioComm Solutions’ SMART Monitoring ECG reading service. This ECG management and interpretation solution will provide physician interpreted or technician triaged ECG reports to the consumer within one hour on a fee-for-service basis. CardioComm Solutions’ current infrastructure allows the SMART Monitoring ECG service to support ECG transmissions from anywhere globally. With the Australian clearance, the Company will be looking to expand ECG services to support arrhythmia management of patients through a localized SMART Monitoring installation and ECG call service..

CardioComm Solutions has been working to globally expand its two main business verticals involving the sale of its consumer-based, OTC HeartCheck™ ECG monitoring products and their newly released, physician/hospital focused GEMS™ WIN ECG management solutions. The Company has approvals for the sale of the HeartCheck™ devices in Canada, the United States of America, the European Union, China and Australia.

More information regarding the HeartCheck™ products and SMART monitoring solutions is available at the Company’s web site www.theheartcheck.com.

About CardioComm Solutions

CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions, Inc. is headquartered in Toronto, Canada, with offices in Victoria, B.C.

For more information please contact investorrelations@cardiocommsolutions.com.



Forward-looking statements

This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should: not place undue reliance on forward-looking statements and forward-looking information; and be aware the Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this press release other than as required by applicable laws (including without limitation Section 5.8(2) of National Instrument 51-102 (*Continuous Disclosure Obligations*)).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.